Resolution
by the Federal Joint Committee
on an amendment to the Pharmaceutical Directive (AM-RL):
Appendix XII – Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in accordance with the German Social Code, Book Five (SGB V), section 35a
Abiraterone acetate

from 29 March 2012

In its session on 29 March 2012, the Federal Joint Committee resolved to amend the Pharmaceutical Directive (AM-RL), version published 18 December 2008/22 January 2009 (Federal Gazette, number 49a of 31 March 2009), last amended on 15 March 2012 (Federal Gazette, AT 16 April 2012, B6), as follows:

I.

Appendix XII shall be amended in alphabetical order to include the active ingredient abiraterone acetate:

Abiraterone acetate

Therapeutic indication:

Zytiga® is indicated with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

1. Additional benefit of the pharmaceutical over appropriate comparative treatment

a) Patients with metastatic castration resistant prostate cancer whose disease has progressed on or after a docetaxel-based chemotherapy regimen and for whom an additional regimen of docetaxel is not advisable.

Appropriate comparator: palliative treatment with dexamethasone, prednisone, prednisolone or methyl-prednisolone, as well as best supportive care (e.g. appropriate pain therapy).

Best supportive care (BSC) is understood to be the therapy that provides the best possible individual supportive treatment for the patient to relieve symptoms and improve quality of life.

Extent and probability of additional benefit over best supportive care: indication of a considerable additional benefit.

Study results according to endpoints:

	Effect estimates [95% CI] abiraterone acetate + prednisone + BSC vs. placebo + prednisone + BSC	Result/incident rate Absolute difference (AD)[1]	p-value
Mortality			
Overall survival[2]	HR 0.74 [0.64; 0.86]	Median: 482 days (15.8 months[3]) vs. 341 days (11.2 months[3]), AD = 141 days (4.6 months[3])	<0.001
Morbidity			
Time until first skeletal incident[2]	HR 0.62 [0.48; 0.79]	25% quantile[4]: 301 days (9.9 months[3]) vs. 150 days (4.9 months[3]), AD = 151 days (5.0 months[3])	<0.001
Time until pain progression[2]	HR 0.69 [0.53; 0.88]	25% quantile[4]: 225 days (7.4 months[3]) vs. 142 days (4.7 months[3]), AD = 83 days (2.7 months[3])	0.003

	Effect estimates [95% CI] abiraterone acetate + prednisone + BSC vs. placebo + prednisone + BSC	Result/incident rate Absolute difference (AD)[1]	p-value
Health-related quality of life			
Quality of life[5]	The data provided by the pharmaceutical company are not suitable for making robust statements on the additional benefit for this endpoint[5].		
Fatigue[5]	The data provided by the pharmaceutical company are not suitable for making robust statements on the additional benefit for this endpoint[5].		
Side effects[2]			
AE	RR[6] 1.00 [0.99; 1.01]	99.1% vs. 99.0%	0.760
AE of CTCAE degrees 3 and 4	RR[6] 0.99 [0.90; 1.09]	60.4% vs. 60.9%	0.900
SAE	RR[6] 0.97 [0.85; 1.11]	42.4% vs. 43.7%	0.709
Termination due to AE	RR[6] 0.87 [0.69; 1.09]	20.5% vs. 23.6%	0.230
AE leading to death	RR[6] 0.86 [0.64; 1.15]	13.3% vs. 15.5%	0.329

Abbreviations used: CTCAE = common terminology criteria for adverse events, HR = hazard ratio, CI = confidence interval, RR = relative risk, (S)AE = (serious) adverse event

[1] Figures shown for significant differences only
[2] Data from the IQWiG dossier assessment A11-20 for abiraterone, page 20 f.
[3] 365/12 days = 1 month
[4] Shows the time at which the probability of an event occurrence is 25%
[5] Data from the written hearing procedure, IQWiG assessment A11-20 abiraterone acetate, 20 March 2012
[6] Incident rate (IQWiG calculation)

b) Patients with metastatic castration resistant prostate cancer whose disease has progressed after a docetaxel-based chemotherapy regimen, but for whom appropriate chemotherapy with docetaxel may be advisable

Appropriate comparator: docetaxel in combination with prednisone or prednisolone (docetaxel retherapy).

Extent and probability of additional benefit over docetaxel retherapy: As the necessary proof documents for the benefit assessment were not submitted in their entirety, an additional benefit over the appropriate comparator is considered not proved (SGB V, section 35a, paragraph 1, sentence 5).

2. Number of patients and criteria for defining patients eligible for treatment

Target population: approx. 6,300 patients

a) "Best supportive care" patient group

Proportion of target population: 80 to 90%

Number of patients: 5,040 to 5,670 patients

b) "Docetaxel retherapy" patient group

Proportion of target population: 10 to 20%

Number of patients: 630 to 1,260 patients

3. Requirements for quality-assured administration

The specifications outlined in the product information are to be followed.

4. Costs of treatment

a) "Best supportive care" patient group

Duration of treatment:

Description of therapy	Mode of treatment	Number of treatments per patient per year	Duration per treatment (days)	Treatment days per patient per year
Pharmaceutical evaluated				
Abiraterone acetate	ongoing, 1 × 1,000 mg daily	ongoing	365	365
Prednisolone	ongoing, 2 × 5 mg daily	ongoing	365	365

Description of therapy	Mode of treatment	Number of treatments per patient per year	Duration per treatment (days)	Treatment days per patient per year
Appropriate comparator				
Prednisolone	ongoing, 1 × 5 mg daily	ongoing	365	365

Consumption:

Description of therapy	Strength	Number/amount per pack	Average annual consumption
Pharmaceutical evaluated			
Abiraterone acetate	250 mg	120 tablets	1,460 tablets
Prednisolone	5 mg	100 tablets[1]	730 tablets
Appropriate comparator			
Prednisolone	5 mg	100 tablets[1]	365 tablets

[1] Largest pack

Costs:

Cost of pharmaceutical:

Description of therapy	Cost (pharmacy retail price)	Cost after legally mandated rebates[1, 2]
Pharmaceutical evaluated		
Abiraterone acetate	€5,449.91/120 tablets	€4,743.86 (€2.05[1]; €704.00[2])
Prednisolone	€14.61[3]/100 tablets	€12.23 (€2.05[1]; €0.33[2])
Appropriate comparator		
Prednisolone	€14.61[3]/100 tablets	€12.23 (€2.05[1]; €0.33[2])

[1] Rebate in accordance with SGB V, section 130
[2] Rebate in accordance with SGB V, section 130a
[3] Reference price
"Lauer-Taxe", effective 1 March 2012

Costs for additional, necessary statutory health insurance (SHI) benefits: none

Annual treatment costs:

Description of therapy	Annual treatment costs per patient
Pharmaceutical evaluated	€57,806.24
Appropriate comparator	€44.64

b) "Docetaxel retherapy" patient group

Duration of treatment:

Description of therapy	Mode of treatment	Number of treatments per patient per year[1]	Duration per treatment (days)	Treatment days per patient per year
Pharmaceutical evaluated				
Abiraterone acetate	ongoing, 1 × 1,000 mg daily	ongoing	365	365
Prednisolone	ongoing, 2 × 5 mg daily	ongoing	365	365
Appropriate comparator				
Docetaxel	Every 3 weeks 1 × 150 mg	17 cycles[1]	1	17
Prednisolone	ongoing, 2 × 5 mg daily	ongoing	365	365

[1] Standardized calculation for one year

Consumption:

Description of therapy	Strength	Number/amount per pack	Average annual consumption
Pharmaceutical evaluated			
Abiraterone acetate	250 mg	120 tablets	1,460 tablets
Prednisolone	5 mg	100 tablets[1]	730 tablets
Appropriate comparator			
Docetaxel	10 mg/ml	1 x 160 mg/16 ml	17 packs
Prednisolone	5 mg	100 tablets[1]	730 tablets

[1] Largest pack

Costs:

Cost of pharmaceutical:

Description of therapy	Cost (pharmacy retail price)	Cost after legally mandated rebates[1, 2]
Pharmaceutical evaluated		
Abiraterone acetate	€5,449.91/120 tablets	€4,743.86 (€2.05[1]; €704.00[2])
Prednisolone	€14.61[3]/100 tablets	€12.23 (€2.05[1]; €0.33[2])
Appropriate comparator		
Docetaxel	€1,555.73/1 pack	€1,480.31 (€2.05[1]; €73.37[2])
Prednisolone	€14.61[3]/100 tablets	€12.23 (€2.05[1]; €0.33[2])

[1] Rebate in accordance with SGB V, section 130
[2] Rebate in accordance with SGB V, section 130a
[3] Reference price

"Lauer-Taxe", effective 1 March 2012

Costs for additional, necessary statutory health insurance (SHI) benefits:

	Additional necessary SHI expense items			
Description of therapy	Description	Frequency	Number per patient/year	Cost per unit
Appropriate comparator				
Docetaxel	Premedication: Dexamethasone, oral	3 × 8 mg per cycle	17 cycles	€3.35

Annual treatment costs:

Description of therapy	Annual treatment costs per patient
Pharmaceutical evaluated	€57,806.24
Appropriate comparator	€25,311.50

II.

This resolution takes effect on the day of its publication in the internet on the website of the Federal Joint Committee on 29 March 2012.

The justification for this resolution will be published on the website of the Federal Joint Committee at www.g-ba.de.

Berlin, 29 March 2012

The Federal Joint Committee in accordance with SGB V, section 91

The Chair
Hess